S
FULC icon

SignatureFD’s Fulcrum Therapeutics FULC Stock Holding History

SignatureFD’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-68
Closed -$769 – 3524
2025
Q4 		$769 Buy
+68
New +$692 ﹤0.01% 3157
2024
Q4 		– Sell
-162
Closed -$578 – 3339
2024
Q3 		$578 Buy
+162
New +$1.2K ﹤0.01% 3075
2023
Q1 		– Sell
-219
Closed -$1.59K – 3319
2022
Q4 		$1.59K Sell
219
-137
-38% -$893 ﹤0.01% 2871
2022
Q3 		$3K Buy
+356
New +$2.55K ﹤0.01% 2635
2022
Q2 		– Sell
-254
Closed -$6K – 3193
2022
Q1 		$6K Buy
+254
New +$3.6K ﹤0.01% 2394

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SignatureFD's FULC Position: Q1 2026 in Review

SignatureFD sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 68 shares — an estimated $769 sold.

SignatureFD first reported a position in FULC in Q1 2022 and held it in 5 quarters. The position peaked at $6K in Q1 2022. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • SignatureFD reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SignatureFD sold 68 Fulcrum Therapeutics shares in Q1 2026, an estimated $769.
  • SignatureFD first reported a position in Fulcrum Therapeutics in Q1 2022 and held it in 5 quarters.
  • SignatureFD's Fulcrum Therapeutics position peaked at $6K in Q1 2022.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.